10x Genomics Business Summary

10x Genomics, Inc. (TXG) operates a high-margin "razor-and-blade" business model, generating revenue through the sale of proprietary laboratory instruments and the recurring sale of specialized consumables required for their use. The company’s primary business segments are Single Cell (anchored by the Chromium platform) and Spatial Biology (featuring the Visium and Xenium platforms), which enable researchers to analyze biological systems at cellular and sub-cellular resolutions. As of early 2026, the company is increasingly focused on high-growth recurring consumables revenue, which accounts for the vast majority of its total sales, while navigating a constrained capital expenditure environment for instrument sales. 10x Genomics maintains a dominant market share in the single-cell analysis space, competing directly with major life science tool providers such as Illumina, Pacific Biosciences (PacBio), and Twist Bioscience, as well as specialized challengers like Mission Bio and Element Biosciences. Its market position is currently defined by a strategic pivot toward clinical diagnostics and AI-ready spatial datasets through partnerships with organizations like PharosAI and the Dana-Farber Cancer Institute. The company was founded in 2012 by a team of industry veterans including CEO Serge Saxonov, President and CSO Ben Hindson, and former CTO Kevin Ness. Saxonov previously served as the founding architect and director of R&D at 23andMe, while Hindson and Saxonov were both key leaders at QuantaLife prior to its acquisition by Bio-Rad. The current executive leadership team includes CFO Adam Taich, who joined in 2024 from Standard BioTools and Thermo Fisher Scientific, and CTO Michael Schnall-Levin, a founding scientist with a pedigree from the Broad Institute and Foundation Medicine. In January 2026, Dr. Randy Wu transitioned to the role of General Counsel, succeeding the retiring Eric Whitaker. The company is overseen by a board of directors chaired by John Stuelpnagel, a co-founder and former chairman of Illumina, and has historically been backed by prominent institutional investors including Fidelity Investments, Meritech Capital Partners, and Venrock.